INTRODUCTION AND OBJECTIVES: Long noncoding RNAs (lncRNAs) have been implicated in many biological processes and mainly function through epigenetic mechanisms. Our previous study, comparing prostate basal and luminal cells via RNA-seq analysis, found that over 20% of the differentially expressed transcripts are lncRNAs.To explore the biological function and molecular mechanism of dysregulated lncRNAs in prostate cancer (PCa) METHODS: The change of maternal expressed gene 3 (MEG3) gene level in PCa patients was analyzed from multiple dimensions and databases. The consequence of MEG3 dysregulation was determined by its influence on cell proliferation, metastasis and interacting with target genes.Tumor suppressive function was measured through in vivo tumor regeneration assay and in vitro cell viability and mobility assays. The interaction of MEG3 and target was tested by RNA immunoprecipitation (RIP) and RNA pulldown assays. Statistical difference and variances were determined by Student t test or Chi-squared test.
INTRODUCTION AND OBJECTIVES: Steroid 5-alpha reductase (SRD5A2) is a critical enzyme for prostatic development and growth. We have found that epigenetic modifications suppress expression of SRD5A2 in one-third of adult prostates, a condition associated with an androgenic to estrogenic switch in adult prostate tissues accounting for changes in hormonal milieu. Our objective is to demonstrate whether the SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in castration-resistant prostate cancer (CRPC).
METHODS: 58 CRPC samples were used for testing: 42 CRPC prostate biopsies were collected from Massachusetts General Hospital (MGH), and 16 baseline and progression bone biopsies from patients treated with abiraterone and dutasteride (NCT01393730). As controls, 23 benign prostatic specimens were collected from patients with benign prostatic hyperplasia. The methylation status of CpG site(s) at SRD5A2 promoter regions was tested. Data was retrieved on primary and secondary ADT treatment response. Overall survival (OS) was calculated from time of diagnosis to time of death. The protein expression of SRD5A2 was determined with immunohistochemistry in 42 CRPC samples (MGH), and then correlated to SRD5A2 methylation status.
RESULTS: Compared with benign prostatic tissue, CRPC samples demonstrated higher SRD5A2 methylation in the whole promoter region (MGH samples: P < 0.0001; samples from NCT01393730: P [ 0.002). Higher ratio of methylation was correlated with better OS (R2 [ 0.11, P [ 0.032). Hypermethylation of specific regions (nucleotides -434 to -4 (CpG#: -39 to CpG#: -2)) was associated with a better OS (11.3AE5.8 vs 6.4AE4.4 years, P [ 0.001) and progression-free survival (PFS, 8.4AE5 .4 vs 4.5AE3.9 years, P [ 0.005) with cutoff value of 37.9%. Multivariate analysis showed that SRD5A2 methylation was associated with OS independently (whole promoter region: P [ 0.035; specific region: P [ 0.02). The protein expression of SRD5A2 was negatively correlated with its methylation ratio both in the whole promoter region (R2 [ 0.235, P [ 0.0011) and specific region (CpG#: -39 to CpG#: -2) (R2 [ 0.287, P [ 0.0003).
